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The in vitro differentiation and immunosuppressive capacity of mesenchymal stem cells (MSCs)
derived from synovial ﬂuid (SF-MSCs) and bone marrow extract (BM-MSCs) in an isogenic
background of minipigs were comparatively analyzed in a collagen-induced arthritis (CIA) mouse
model of rheumatoid arthritis (RA). The proliferation capacity and expression of pluripotent
transcription factors (Oct3/4 and Sox2) were signiﬁcantly (Po0.05) higher in SF-MSCs than in
BM-MSCs. The differentiation capacity of SF-MSCs into adipocytes, osteocytes and neurocytes was
signiﬁcantly (Po0.05) lower than that of BM-MSCs, and the differentiation capacity of SF-MSCs
into chondrocytes was signiﬁcantly (Po0.05) higher than that of BM-MSCs. Systemic injection of
BM- and SF-MSCs signiﬁcantly (Po0.05) ameliorated the clinical symptoms of CIA mice, with SF-
MSCs having signiﬁcantly (Po0.05) higher clinical and histopathological recovery scores than
BM-MSCs. Furthermore, the immunosuppressive properties of SF-MSCs in CIA mice were
associated with increased levels of the anti-inﬂammatory cytokine interleukin (IL)-10, and
decreased levels of the pro-inﬂammatory cytokine IL-1β and osteoclast-related sRANKL. In
conclusion, SF-MSCs exhibited eminent pluripotency and differentiation capacity into chondro-
cytes, addition to substantial in vivo immunosuppressive capacity by elevating IL-10 and reducing
IL-1β levels in CIA mice.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).lsevier Inc. This is an open access article under the CC BY-NC-ND license
/4.0/).
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Mesenchymal stem cells (MSCs) modulate immune system func-
tion via cell–cell contacts or secretion of soluble factors, making
them ideal candidates for cell therapy to treat certain kinds of
immune-mediated disorders [1–3]. The mechanisms through
which MSCs exert their immunomodulatory functions in auto-
immune diseases have been studied [4–7], but understanding of
these mechanisms is limited due to the diversity of MSCs and the
varying therapeutic effects of MSCs in the collagen-induced
arthritis (CIA) mouse model of rheumatoid arthritis (RA) [4–8].
Although MSCs derived from bone marrow (BM-MSCs) are
commonly used [9], several studies have reported conﬂicting
in vivo results with BM-MSCs in CIA mouse models [4,5].
Synovial ﬂuid (SF) is a signiﬁcant source of MSCs in RA therapy.
SF is an easily accessible source of MSCs, which can be obtained
during diagnosis or treatment of patients when clinicians conﬁrm a
diagnosis of RA without harming [10]. Moreover, the population of
MSCs derived from SF (SF-MSCs) in the synovial cavity of arthritis
patients is highly increased compared to that in healthy patients
[11–13]. Hence, SF-MSCs are excellent candidates for autologous
stem cell therapy in patients with inﬂamed or injured joints.
Despite the potential beneﬁt of using SF-MSCs in the treatment
of arthritis or other diseases, the majority of studies of MSCs
derived from synovial sources have employed MSCs from syno-
vium (SM-MSCs) rather than synovial ﬂuid [14,15]. These studies
compared the characteristics and differentiation potential of SM-
MSCs and SF-MSCs derived from patients with RA or osteoarthritis
(OA) into osteogenic or chondrogenic lineages [11,13], and esti-
mated that the diversity of the original source of MSCs can
substantially affect the characteristics of MSCs. Therefore, it should
be needed to understand the correlation of cell source-dependent
in vivo immunosuppressive properties with in vitro characterization
in an isogenic background for the cell therapy of RA. To shed light
on the immunomodulation properties of MSCs in RA treatment, the
in vitro characteristics of MSCs that affect their function and
immunosuppressive properties in vivo need to be determined
using suitable animal models of RA. Based on their similar genetic
and immunomodulatory characteristics to humans, minipigs were
used as model animals in the present study. According to a
previous study, minipigs may render important insights into our
understanding of MSCs and the application of MSCs in human
therapies [15].
Anti-inﬂammatory therapies for RA, such like antitumor necro-
sis factor (anti-TNF) agents, have been widely used to prevent or
delay the progression of joint cartilage and bone destruction, but
they do not regenerate damaged tissues. MSCs possessing
enhanced immune-modulation and multilineage differentiation
properties seem to be the best candidates for cell therapy of RA to
regenerate damaged cartilage/bone. SF-MSCs might be one of the
best candidates as they can be easily obtained.
Hence, in the present study, we evaluated the proliferation and
multilineage differentiation capacities of SF- and BM-MSCs in an
isogenic background of minipigs. Furthermore, the immunosup-
pressive functions and therapeutic effects of SF- and BM-MSCs
were evaluated following systemic injections into CIA mice. The
results suggest that SF-MSCs possess immunosuppressive func-
tions, facilitating systemic recovery from RA by promoting carti-
lage or bone repair in damaged RA joints.Materials and methods
All media and chemicals were purchased from Gibco (Invitrogen
Corporation, Grand Island, NY, USA) and Sigma-Aldrich Chemical
Company (St. Louis, MO, USA) unless otherwise speciﬁed. The
MSC culture medium was advanced Dulbecco’s modiﬁed Eagle
medium (ADMEM), supplemented with 10% of fetal bovine serum
(FBS), 1% GlutaMax (Gibco), 10 ng/mL of basic ﬁbroblast growth
factor (bFGF), and 1.0% penicillin–streptomycin (10,000 IU and
10,000 μg/mL, respectively, Pen-Strep), The osmolarity was adjus-
ted to 28575 mOsm/kg, and the pH was adjusted to 7.2.
Cell isolation and culture of BM- and SF-MSCs from
minipigs
All animal experiments, cell isolation, and cell injection were
authorized by the Animal Center for Biomedical Experimentation
at Gyeongsang National University. The two types of MSCs (i.e.,
BM-MSCs and SF-MSCs) were established from three sexually
mature 6-month-old male minipigs (T-type, PWG Micro-pig, PWG
Genetics Korea, Ltd.). BM was extracted from iliac crest bone
biopsies and processed for isolation of MSCs, as previously
described [16]. The extracts were layered onto a Ficoll density
gradient (Amersham Biosciences, Uppsala, Sweden) and centri-
fuged at 400 g for 40 min at 20 1C. The interface buffy layer was
collected and washed with Dulbecco’s phosphate-buffered saline
(PBS) twice to isolate cell populations. SF from the femorotibial
joint was biopsied by syringe aspiration. After ﬁltering the SF
through a 40 μm nylon cell strainer (BD Falcon, Becton Dickinson
Franklin Lakes, NJ, USA) to remove debris, cells were isolated by
centrifugation at 400 g for 10 min. Explants were attached onto
35 mm dishes (Nunc, Roskilde, Denmark) and cultured in 2 mL of
culture media. After the elimination of explants, the attached cells
were cultured. Both types of cells were then cultured in the MSC
culture medium at 38.5 1C in a humidiﬁed atmosphere of 5% CO2
in air, and the medium was changed twice a week. On reaching
conﬂuence, the cells were trypsinized with 0.25% trypsin-EDTA
solution and pelleted by centrifugation. The cells were then
grown to passage 3 for further experiments.
Analysis of cell surface markers
Cell surface antigens of MSCs were analyzed by ﬂow cytometry
analysis (BD FACS Calibur; Becton Dickinson Franklin Lakes, NJ,
USA), as previously described [17]. Brieﬂy, BM- and SF-MSCs at
80–90% conﬂuence were ﬁxed with 4% paraformaldehyde. They
were labeled with FITC-conjugated isotype IgG antibodies (con-
trol); FITC-conjugated anti-CD34, anti-CD44, anti-CD45, and/or
anti-CD90 antibodies; and/or anti-CD29, anti-vimentin, and/or
anti-MHC class II primary antibodies with FITC-conjugated sec-
ondary antibodies. All antibodies were diluted 1:200 (Table 1).
Cell proliferation assay
To evaluate the cell proliferation capacity, 1103 cells at passage
3 were suspended in 500 μL of ADMEM, supplemented with 10% FBS
and cultured for 14 days, and the culture medium was changed
every 3 days. Cells were harvested with 0.25% trypsin EDTA every 2
days and counted in triplicate with a hemocytometer.
Table 1 – Antibodies for the evaluation of cell surface markers by FACS.
Antibody Company Amount Dilution
FITC goat anti-mouse IgG BD Pharmingen 0.5 mg/mL 1:100
Mouse anti-pig CD29 BD Pharmingen 0.5 mg/mL 1:100
FITC mouse anti-human CD 34 BD Pharmingen 0.5 mg/mL 1:100
FITC rat anti-mouse CD 44 BD Pharmingen 0.5 mg/mL 1:100
FITC rat anti-mouse CD 45 BD Pharmingen 0.2 mg/mL 1:100
FITC mouse anti-human CD 90 BD Pharmingen 0.5 mg/mL 1:100
Mouse anti-vimentin SIGMA-Aldrich 0.5 mg/mL 1:100
Mouse anti MHC class II Santa Cruz Biotechnology 0.2 mg/mL 1:100
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The differentiation and conﬁrmation of adipogenic and osteogenic
induction were performed as previously described [16,18]. Brieﬂy,
the cells were cultured for 3 weeks in DMEM containing 10% FBS,
100 mM indomethacin, 10 mM insulin, and 1 mM dexamethasone for
adipogenic differentiation and 10% FBS, 200 mM ascorbic acid,
10 mM β-glycerophosphate, and 0.1 mM dexamethasone for osteo-
genic differentiation. Adipogenic differentiation was determined by
staining intracellular lipid vacuoles using 0.5% Oil red O solution.
Osteogenic differentiation was identiﬁed by the accumulation of
calcium deposits and proteoglycan following staining with 5% sliver
nitrate solution (Von Kossa staining) and 1% Alcian blue solution.
Cartilage pellets were formed using a modiﬁed conventional pellet
culture method [19]. In brief, 1106 cells at passage 3 were
suspended in 500 mL of STEMPRO chondrogenesis differentiation
media with 10% supplement (Gibco) in a 15mL tube. After centrifu-
gation at 450 g for 5 min, the pellets were cultured for 3 weeks. For
Alcian blue staining, the pellets were processed into parafﬁn-
embedded sections on glass slides after dehydration, and the slides
were then stained with 1% Alcian blue solubilized in 3% acetic acid
(pH 2.5) for 10min, with counter staining of 0.1% nuclear fast red
solution for 1 min to conﬁrm synthesis of proteoglycans. The slides
were mounted with Permount™ after dehydration. Immunocyto-
chemical staining was performed to detect the expression of aggrecan
(ACAN) [20]. After deparafﬁnization and hydration, the slides were
incubated with goat polyclonal ACAN (cartilage-speciﬁc proteoglycan
core protein, 1:200 dilution; Santa Cruz Biotechnology, Inc., Europe)
for 2 h, followed by incubation with FITC-conjugated secondary
antibodies (1:200 dilution; donkey antigoat IgG-Texas red antibody,
Santa Cruz Biotechnology, Inc., Europe) for 45min in 37 1C. Nuclei
were counterstained with 1 mg/mL pf 40,6-diamidino-2-phenylindole
(DAPI) solution for 5 min. Sectioned pellets exhibiting red and blue
stains under a ﬂuorescence microscope (Nikon, Tokyo, Japan) were
determined to be positive.
Neurogenic differentiation was induced as previously reported [18].
MSCs were cultured overnight with neurogenic preinduction media
(i.e., DMEM supplemented with 20% FBS and 10 ng/mL of bFGF). The
cells were then cultured in DMEM, supplemented with 2% of dimethyl
sulfoxide, 200 mM of butylated hydroxyanisole, 2 mM of valproic acid,
10 mM of forskolin, 5 mg/mL of insulin, 1 mM of hydrocortisone, and
25mM of KCl for 6 h. Expression of neuron-speciﬁc markers was
determined by immunocytochemical staining. Fixed cells were incu-
bated with primary antibodies targeting neuroﬁlament M (NFM),
nerve growth factor (NGF), and tropomyosin related kinase A (TRKA;
Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200 dilution) for 2 h,followed by incubation with FITC-conjugated secondary antibody
(Jackson ImmunoResearch, PA, USA; 1:200 dilution) for 45min at
37 1C. Nuclei were stained with DAPI for 5 min, and images were
observed under a ﬂuorescence microscope (Nikon, Tokyo, Japan).Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) analysis
To evaluate lineage-speciﬁc gene expression, total RNA was
extracted using an RNeasy minikit (Qiagen, Valencia, CA, USA) and
quantiﬁed using an OPTIZEN 3220 UV BIO spectrophotometer
(Mecasys Co., Ltd., Korea). To synthesize cDNA, reverse transcription
was performed from 1 mg total RNA using an Omniscript Reverse
Transcription Kit (Qiagen) with oligo dT primer (Invitrogen) at 60 1C
for 1 h. Relative qRT-PCR was performed using LightCyclerTM with
FastStart DNA Master SYBR Green I (Roche), which consists of 2 mM
of MgCl2, 2 mL of SYBR Green, and 0.5 mM each of forward and
reward primers. The ampliﬁcation program consisted of denatura-
tion at 95 1C for 1 min, followed by 50 PCR cycles at 95 1C for 10 s,
60 1C for 6 s, and 72 1C for 4 s and melting curve analysis (65 1C to
95 1C, with increases of 0.1 1C per second, cooling at 40 1C for 30 s).
All transcriptional levels of target genes were normalized against a
reference gene, hydroxymethylbilane synthase (HMBS). The primers
used for the study are listed in Table 2.Injection of MSCs into CIA mice
Pathogen-free male DBA/1 mice (aged 7–9 weeks) were pur-
chased from Orient Bio (Seoul, Korea), and CIA was induced as per
previously described methods [21]. The CIA mice were divided
into three treatment groups: phosphate-buffered saline (PBS)
injection (control), BM-MSC injection, and SF-MSC injection
(n¼5 per group; experiments were performed three times).
Treatment was initiated after the onset of disease (day 22), when
arthritis had become established (arthritis score Z1). Intraper-
itoneal injection (i.p.) of MSCs was performed as previously
described [7], with minor modiﬁcations. Brieﬂy, CIA mice received
an i.p. injection each day for 5 days with PBS alone (control) or
with 3106 BM-MSCs or SF-MSCs obtained from the minipig.
Clinical arthritis and severity scores were evaluated in each limb
using previously described protocols [22]. Hind paw thickness was
measured with electronic calipers placed across the ankle joint at
the widest point.
Table 2 – Primer sequence of early transcriptional factors and lineage speciﬁc marker genes.
Target gene Sequence Annealing temp (1C) Reference
Forward Reward
Oct3/4 acaaggagaagctggagccga aggagcttggcaaattgttcgagat 60 NM_001113060.1
Sox2 catgcaccgctacgacgtga ggcgagccgttcatgtaggt 60 NM_001123197.1
Nanog tggaaacctgcccgtgtggg tggctgttccaggtctggttgc 60 NM_001129971.1
Adipocyte protein 2 (aP2) tggtacaggtgcagaagtggga gccgtgacacctttcatgataca 60 NM_001002817.1
Fatty acid binding protein (FABP) ccgagagctgatccaatggttgc gcggggacacaggctccact 60 NM_214379.1
Lipoprotein lipase (LPL) caaacttgtggctgccctat aaggctgtatcccaggaggt 60 NM_214286
RUNX2 cagaccagcagcactccata cggtagcattctggaaggag 60 EU668154.1
Osteonectin (ON) gaaagttccagaacccacca gcgagagcgtctgtatttcc 60 NM_001031794
Biglycan (BG) ggagctcggagatgtcgtta gtcgtccagtgctctgacct 60 AU055629
Myelin basic protein (MBP) gagatggctcaactcagaacg ggttagtatttgccgtgagca 60 NM_001001546
Nestin ggcttctctcagcatcttgg aaggctggcataggtgtgtc 60 XM_001925549
β3-Tubulin cagagcaagaacagcagctactt gtgaactccatctcgtccatgccctc 60 XM_03355721
Aggrecan (ACAN) aagaccatcgaaggggactt cagtggcgaagaagttgtca 60 NM_001164652.1
Collagen type2 (COL2) gagaggggagctgctggtat tcccttctcaccgttagcac 60 XM_001925959
Collagen type10, alpha 1 (COL10A1) gacaaccaggcatcaaaggt caatgccttctcgtccttgt 60 NM_001005153.1
Hydroxymethylbilane synthase (HMBS) aggatgggccaactctacctg gatggtggcctgcatagtct 60 DG845174
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The mice were sacriﬁced 40 days after the primary injection, and
joint tissues were harvested from each mouse for end-point
histological assessment and measurement of cytokines. Joint
tissues were ﬁxed with 10% formalin, decalciﬁed for 3 weeks in
10% EDTA, dehydrated, and embedded in parafﬁn. Joint sections
(5 μm) were stained with hematoxylin and eosin (H&E) for
observation of articular destruction and Safranin O staining for
evaluating cartilage maintenance. All stained joint sections were
observed at 100 magniﬁcation using a light microscope.
The histological scores of the joint sections stained with H&E
and Safranin O were evaluated using previously described proto-
cols [21,23,24]. In detail, inﬂammation was analyzed using a scale
of 0–5, in which 0¼normal; 1¼equivocal/minimal; 2¼obvious,
but mild and focal; 3¼moderate, with thickness of inﬂammatory
tissue less than half that of bone; 4¼severe, with thickness of
inﬂammatory tissue more than half that of bone; and 5¼very
severe, with thickness of inﬂammatory tissue greater than that of
bone. Bone erosion was scored using a scale of 0–5, in which
0¼normal; 1¼equivocal/minimal; 2¼obvious, but mild;
3¼moderate, without full-thickness defects in the cortex;
4¼severe, with full-thickness defects in the cortex; and
5¼extreme, with distortion of the remaining cortical surface.
Cartilage damage was estimated using a scale of 0–5, in which
0¼normal; 1¼equivocal/minimal; 2¼obvious, but mild and
focal; 3¼moderate, with thickness of cartilage loss less than half
of total cartilage depth; 4¼severe, with thickness of cartilage loss
more than half of total cartilage depth; and 5¼very severe and
diffuse, with almost complete loss of cartilage.
Pro- and anti-inﬂammatory cytokine levels were determined in
serum and ankle joint samples obtained on day 40. Cytokine levels
were determined using a Quantikine enzyme-linked immunosorbent
assay (ELISA) (R&D Systems, Minneapolis, MN, USA). Protein was
extracted from ankle joints by homogenization (50mg of tissue/mL)
in lysis buffer (mammalian protein extraction reagent; Pierce, Rock-
ford, IL, USA) containing a proteinase inhibitor cocktail (Calbiochem,San Diego, CA, USA). Tumor necrosis factor-α (TNF-α), interleukin (IL)-
1β, IL-6, IL-10, and soluble receptor activator of nuclear factor κB
ligand (sRANKL) were measured using speciﬁc ELISA kits.
Statistical analysis
One-way analysis of variance (ANOVA) with Tukey’s posthoc test
was used to analyze differences among the treatments using SPSS
software. Data are expressed as the mean7standard error of the
mean (SEM), and differences were considered signiﬁcant when
P-values were less than 0.05.Results
Cell surface markers for MSCs
In both BM- and SF-MSCs, cell surface markers, including CD29,
CD44, CD90, and vimentin, were highly expressed (Z96–99% of
positive cells), whereas the expression of CD34 and CD45 was low
(r2% of positive cells; Fig. 1A). The expression of MHC class II
molecules was low in both types of MSCs, with the lowest level
(0.08% of positive cells) observed in SF-MSCs.
Cell proliferation capacity of MSCs
As shown in Fig. 1B, the population of cells derived from SF
(5.32105 cells/well) was signiﬁcantly higher at 14 days after
seeding than the population of cells derived from BM 4.16105
cells/well; Po0.05), indicating that the proliferation capacity of
MSCs derived from SF-MSCs is greater than that of BM-MSCs.
Transcriptional factors of MSCs
Both BM- and SF-MSCs expressed Oct3/4, Sox2, and Nanog, but the
level of expression of each marker varied. The expression of Oct3/4
Fig. 1 – Analysis of cell surface markers, proliferation, and transcription factors in BM-and SF-MSCs at passage 3. (A) Cell surface
markers of BM- and SF-MSCs were identiﬁed by FACS analysis. MSCs were identiﬁed in cells positive for CD29, CD44, CD90, and
vimentin and negative for CD34, CD45, and MHC class II. (B) The proliferation capacities of BM- and SF-MSCs were evaluated for 14
days. Values indicated are the mean7SEM of three replicates. * Indicates a signiﬁcant (Po0.05) difference between the BM- and SF-
MSCs. (C) The expression of stem cell transcriptional factors Oct3/4, Sox2, and Nanog was analyzed by qRT-PCR. Five replicates were
used, and HMBS was employed as an internal control gene. Bars with * indicate a signiﬁcant (Po0.05) difference between the BM-
and SF-MSCs.
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BM-MSCs, but Nanog expression did not differ (Fig. 1C).
Multilineage differentiation capacity of MSCs
Cytochemical staining veriﬁed that MSCs from both sources
progressed toward differentiation into adipocytes and osteocytes,
as conﬁrmed by the cytoplasmic accumulation of lipid vacuoles
and the deposition of calciﬁed extracellular matrix by Oil red O,
Von Kossa, and Alizarin red S staining, respectively (Fig. 2A and C).
In speciﬁc cytochemical staining, adipogenic and osteogenic
differentiated BM- and SF-MSCs showed strong positive stains.
However, the intensity of staining did not differ among these
MSCs on gross observation.
Adipogenesis- and osteogenesis-related genes associated with
BM- and SF-MSCs were analyzed before and after the induction of
differentiation (Fig. 2B and D). Three adipocyte-related genes
(adipocyte fatty acid binding protein [aP2], fatty acid binding protein[FABP], and lipoprotein lipase [LPL]) in both MSCs after differentia-
tion into adipocytes showed increased expression compared to the
undifferentiated state. The levels of FABP and aP2 were signiﬁcantly
higher (Po0.05) in differentiated adipocytes from BM-MSCs than in
those from SF-MSCs. In contrast, the level of LPL was signiﬁcantly
higher (Po0.05) in the SF-MSCs than in the BM-MSCs (Fig. 2B). The
expression of Runx2, an early osteogenesis marker, in the SF-MSCs
decreased signiﬁcantly (Po0.05) after differentiation, whereas its
expression increased in BM-MSCs. In addition, the expression of the
osteocyte-speciﬁc genes, biglycan and osteonectin, was signiﬁcantly
(Po0.05) higher in all kinds of osteogenic-induced MSCs compared
to the undifferentiated state (Fig. 2D).
During induction of neuronal differentiation, BM- and SF-MSCs
acquired a bipolar, stellate morphology consistent with that of
sensory and motor neurons (Fig. 3A). They were positively labeled
with NFM, NGF, and TRKA neuron-associated proteins by immu-
nocytochemical staining (Fig. 3C). The expression of myelin basic
protein [MBP], β-tubulin, and nestin was signiﬁcantly (Po0.05)
Fig. 2 – Adipogenic and osteogenic differentiation potential of BM-and SF-MSCs. Adipogenic and (osteogenic differentiation was
induced for 3 weeks at 3 passages. Adipogenic (A) and osteogenic (C) induction was assessed by Oil red O staining of intracellular
accumulation of neutral lipid vacuoles and Von Kossa and Alizarin red S staining of mineralized matrix formation, respectively.
Bars 100 μm. (B) Adipogenic differentiation was evidenced by the expression of aP2, FABP, and LPL by qRT-PCR. (D) Osteogenic
differentiation was demonstrated by the expression of osteonectin, Runx2, and biglycan by qRT-PCR. Five replicates were used, and
HMBS was employed as an internal control gene. Bars with an * indicate a signiﬁcant (Po0.05) difference between the
undifferentiated control and differentiated cells. White bar: undifferentiated cells; dark gray bar: differentiated cells; U;
undifferentiated cells, A: adipogenic differentiated cells; O: osteogenic differentiated cells. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Fig. 3B). The expression of neurocyte-related genes in SF- and
BM-MSCs in the undifferentiated state was similar. However,
upon the induction of neurogenesis, their expression was sig-
niﬁcantly (Po0.05) higher in BM-MSCs as compared to SF-MSCs.
BM- and SF-MSCs were successfully aggregated by pellet culture
for chondrogenic induction. In both cases, the chondrogenic pellets
had a similar spherical and glistening transparent appearance
(Fig. 4D). SF-MSC-induced chondrogenic pellets gradually increased
in size during 3 weeks of culture. In contrast, the pellets induced
from BM-MSCs gradually increased in size until 2 weeks after
induction and thereafter showed no signiﬁcant change in size.
Three weeks after induction, the mean diameter of the SF-MSC
chondrogenic pellets (22.772.8 mm) was signiﬁcantly (Po0.05)
larger than that of the BM-MSC pellets (17.172.1 mm) (Fig. 4B).
In the chondrogenic pellets from SF-MSCs, Alcian blue staining
was observed in the central area at 1 week after the induction of
chondrogenesis (Fig. 4A). Proteoglycan deposits in chondrocytes
induced in differentiated zones exhibited positive staining, and the
chondrocytes had a broad, spindle cell-like morphology. After 3
weeks of induction, these cells grew, showing multilayered organi-
zation in pellets. ACAN was expressed in the BM- and SF-MSC-
derived pellets at 1 week after induction (Fig. 4B). The expression of
ACAN was increased in the chondrogenic pellets at 2 weeks after
induction in both types of MSCs. The expression levels of collagen
type 2 (COL2), collagen type X alpha 1 (COL10A1), and ACAN were
evaluated in the MSCs before and after 3 weeks of differentiation
into chondrocytes (Fig. 5A). The levels of COL2 and COL20A1 weresigniﬁcantly higher (Po0.05) in differentiated chondrocytes from
SF-MSCs than in those from BM-MSCs during 3 weeks of induction.
The expression of ACAN gradually increased following differentia-
tion. However, the expression did not exactly match the result of
immunocytochemical staining. The level of ACAN was highest in SF-
MSCs at 3 weeks after induction.Immunosuppression in CIA mice following treatment with
MSCs
The mean arthritis scores of CIA mice following i.p injections of BM-
and SF-MSCs were signiﬁcantly lower than those of PBS-injected
control mice (Fig. 6A; Po0.05 and Po0.01, respectively). These
scores indicate that RA recovery was signiﬁcantly better in the SF-
MSCs injected mice than in the PBS-injected mice (Po0.01). The
hind paw thicknesses of the SF- and BM-MSC injected CIA mice
were signiﬁcantly (Po0.01) lower than those of control mice, but
they did not differ signiﬁcantly among the mice treated with either
type of MSC (Fig. 6B). Histopathological observations showed that
the joints of the control mice exhibited prominent synovial inﬂam-
mation (asterisk), cartilage damage (arrow), and bone erosion
(arrowhead) (Fig. 7A and B). In contrast, the MSC-injected CIA mice
showed decreased pathological manifestations. In addition, the
injection of SF-MSCs signiﬁcantly (Po0.01) suppressed arthritis in
CIA mice (Fig. 7A and B).
Analysis of pro-/anti-inﬂammatory cytokine levels in the MSC-
injected CIA mice in joint tissues and sera at 40 days after CIA
induction revealed that the expression levels of TNF-α and IL-6
Fig. 3 – Neuronal differentiation potential of BM-and SF-MSCs. (A) Following neuronal induction, BM- and SF-MSCs exhibited
typical neuron-like cells, with multipolar, round cell bodies forming a network-like structure. (B) Neuronal differentiation was
demonstrated by the expression of β-tubulin,myelin basic protein, and nestin by qRT-PCR. Five replicates were used, and HMBS was
employed as an internal control gene. Bars with an * indicate signiﬁcant (Po0.05) differences between the undifferentiated control
and differentiated cells. White bar; undifferentiated cells; dark gray bar; differentiated cells; U: undifferentiated cells, N:
neurogenic differentiated cells. (C) Expression of neuron-speciﬁc antigens, such as NFM, NGF, and TRKA, were detected by
immunoﬂuorescence staining. DAPI (blue), green indicates the positive reactivity of marker proteins with secondary antibodies,
Bars 100 μm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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among the groups (Fig. 7C). On the other hand, the level of
another pro-inﬂammatory cytokine, IL-1β in ankle tissues of the
SF-MSC-injected CIA mice was signiﬁcantly (Po0.05) lower than
in the control and BM-MSC-injected CIA mice. The osteoclast-
speciﬁc sRANKL expression level in ankle tissues of the SF-MSC-
injected CIA mice was signiﬁcantly (Po0.01 and Po0.05) lower
than in the control and BM-MSC-injected mice. However, the level
of IL-10 (an anti-inﬂammatory/regulatory cytokine) in ankle
tissues and serum of the SF-MSC-injected CIA mice were sig-
niﬁcantly (Po0.05) higher than in the control and BM-MSC-
injected mice (Fig. 7D). These results suggest that SF-MSCs
ameliorate the severity of CIA by preventing cartilage/bone
destruction and increasing IL-10 levels in ankle tissue and serum,
indicating that SF-MSCs may have strong therapeutic efﬁcacy.Discussion
Ideal MSC candidates in RA therapy would have enhanced multi-
lineage differentiation and immune-modulation potential for repair-
ing not only destructed cartilage or bones in affected joints but also
ameliorating the autoimmune response to chronic systemic inﬂam-
mation. SF-MSCs can be easily and noninvasively obtained as a cell
source for stem cell therapy by aspirating SF with a needle andsyringe from the joints of patients diagnosed with RA [10–13,19].
Until now, the immune-suppression potential of MSCs derived from
synovial sources in the treatment of RA has not been investigated.
Most studies that have focused on SF-MSCs have examined char-
acteristics of cells derived from OA or injured joints in patients who
may have different physiological statuses [11–13]. Therefore, in the
present study, we investigated whether SF-MSCs have proliferation
and differentiation potential and immune-suppression capacities by
comparing them with BM-MSCs. Moreover, we compared cell
source-dependent immune-suppression properties of BM- and SF-
MSCs derived from minipigs with an isogenic background and
evaluated the therapeutic potential of these different MSCs using
CIA mice to acquire a complete understanding of speciﬁc character-
istics of both types of cells.
In the present study, homogenous adherent SF-MSC and BM-MSCs
not only had similar ﬁbroblastic spindle shapes but also comparable
expression patterns of CD markers [27], as reported previously in
human patients [28–30]. Although the expression of the MHC class II
surface antigen was lower in SF-MSCs than in BM-MSCs, the
difference was not signiﬁcant, suggesting that SF-MSCs would result
in minimal immune rejection in clinical applications [28].
The proliferative ability of MSCs and the expression of stem cell
transcription factors serve as reliable indicators of the self-renewal
capacity of MSCs. High proliferative ability would enhance popula-
tions of cells for use in clinical applications. In the present study,
Fig. 4 – Time course of in vitro chondrogenic differentiation potential of BM- and SF-MSCs. In vitro chondrogenesis was assessed by
cytochemical and immunocytochemical staining and measurement of chondrogenic pellet size 1, 2, and 3 weeks after induction.
(A) Chondrogenic induction was demonstrated by Alcian blue staining of proteoglycan deposits in pellets 1, 2, and 3 weeks after
cultivation. Bars 100 μm, 100 and 200 magniﬁcation. (B) Sectioned chondrogenic pellets were stained with ACAN, a cartilage-
speciﬁc proteoglycan core protein, and its expression was assessed by immunocytochemical staining. Bars 100 μm. DAPI (blue)
indicates the nucleus, and violet ﬂuorescence shows the merged image with ACAN (red). (C) The diameters of the chondrogenic
pellets were measured 1, 2, and 3 weeks after induction. The different superscripts (a,b, and c) represent signiﬁcant (Po0.05)
differences among 1, 2, and 3 weeks of differentiated cells after chondrogenic induction (1 w, 2 w, and 3 w: 1, 2, and 3 weeks after
the induction of differentiation) in three replicates. (D) Morphology of pellets 3 weeks after induction of chondrogenesis of BM-
and SF-MSCs. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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Furthermore, the expression of the transcription factors Oct3/4
and Sox2 was higher in SF-MSCs than in BM-MSCs, indicating that
SF-MSCs have comparatively greater pluripotency. Oct3/4 is a most
important early transcriptional factor for maintaining pluripotency
and highly expressed in MSCs with Sox2 and Nanog [31]. We
compared the proliferation and pluripotency capacities of SF-MSC
and BM-MSCs from clinically normal isogenic animals and eval-
uated the characteristics of the cells following the induction of
differentiation. In previous studies of patients with OA or anterior
cruciate ligament injury, the population of MSCs in the SF increased
in accordance with the progression of inﬂammation (i.e., radiolo-
gical grading), especially in SF-MSCs in patients with intra-articular
ligament injury where they were seven and 100 times moreabundant than those in patients with early-stage OA [11] and
healthy humans [12], respectively. As reported previously in CIA
mice, the canal that connects the joint space with the BM
compartment becomes enlarged, resulting in increased migration
of BM cells into the synovial space [32]. Given the high level of
transcriptional factors, greater proliferation capacity, large popula-
tion, and easy availability of SF-MSCs from the affected joint space
of patients, SF-MSCs appear to be an excellent source of cells for
autologous stem cell therapy. However, Jones et al. [30] reported
that the numbers of clonogenic synovium-derived MSCs in inﬂam-
matory arthritis were greater in OA compared to RA and other
arthropathies. Despite the pathological environment of the joints,
the phenotype and the characteristics of multipotent synovium-
derived MSCs were similar to those of BM-MSCs [30]. Therefore,
Fig. 6 – Evaluation of clinical scores in CIA mice treated with BM- and SF-MSCs. CIA mice were injected with PBS, BM-SC, or SF-MSCs
on day 22 (1 day after booster immunization on day 21). (A) Evaluation of the mean arthritis scores and (B) hind paw thickness of
CIA mice following the i.p. injection of MSCs. The * indicates signiﬁcant (*Po0.05, **Po0.01) differences between the PBS control
and MSC-injected mice. Values indicate the mean and SEM of three independent experiments.
Fig. 5 – Expression of chondrocyte-speciﬁc genes in BM- and SF-MSCs 3 weeks after induction of chondrogenesis. In vitro
chondrogenic differentiation was demonstrated by the expression of COL2, ACAN, and COL10A1 by qRT-PCR 1, 2, and 3 weeks after
induction. Five replicates were used, and HMBS was employed as an internal control gene. The different superscripts (a,b,c,d, and e)
represent signiﬁcant (Po0.05) differences among undifferentiated control, and 1, 2, and 3 weeks of differentiated cells after
chondrogenic induction (0 w: undifferentiated cells; 1 w, 2 w, and 3 w: 1, 2, and 3 weeks after the induction of differentiation,
respectively).
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function of synovium- or synovial ﬂuid-derived MSCs from RA
patients should be characterized to determine their potential as
autologous stem cell therapy.
In the present study, although both BM- and SF-MSCs success-
fully differentiated into multilineages, their differentiation poten-
tial in terms of lineage-speciﬁc gene expression patterns was
slightly different. Although the SF-MSCs had a lower ability to
differentiate into adipocytes than BM-MSCs, the expression of the
preadipocyte related LPL gene was higher in SF-MSCs than BM-
MSCs. There was a high level of Runx2, one of most important
osteogenic gene markers, in undifferentiated SF-MSCs, but thelevel decreased following differentiation into osteocytes. LPL and
Runx2, both important lineage-speciﬁc genes, altered the dynamic
equilibrium between osteogenesis and adipogenesis, with over-
expression of Runx2 inhibiting adipogenesis by suppressing the
expression of LPL at the mRNA level [33]. These ﬁndings suggest
that down-regulation of Runx2 in differentiating osteocytes is
directly correlated with extreme up-regulation of LPL in differ-
entiating adipocytes from SF-MSCs.
A previous study reported that SF-MSCs isolated from patients
with temporomandibular joint disorder showed neurogenic dif-
ferentiation capacity [34]. Similarly, we conﬁrmed that SF-MSCs
isolated from minipigs have neurogenic differentiation abilities,
Fig. 7 – Therapeutic effects in CIA mice treated with BM- and SF-MSCs. Histopathological severity and the production of cytokines
were evaluated in CIA mice following an i.p. injection of MSCs. (A) Mean histological scores of sectioned joints and (B) staining
with hematoxylin and eosin (H&E). Safranin O was employed for histological evaluation of the joints of the CIA mice 19 days after
MSC injection. The arrow indicates cartilage destruction, the arrowhead indicates subchondral bone erosion, and the asterisk
denotes the presence of inﬂammatory inﬁltrates in the synovial tissue. (C and D) Levels of pro- and anti-inﬂammatory cytokines,
TNF-α, IL-1β, IL-6, and IL-10 were measured in joint tissues and the sera of CIA mice using ELISA. Level of osteoclast-speciﬁc
sRANKL was measured in the joint tissues of CIA mice using ELISA. The * indicates signiﬁcant (*Po0.05 and **Po0.01) differences
between the PBS and MSC-injected mice. (Original magniﬁcation 20. Bars¼500 μm).
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lower than in BM-MSCs. Analysis of the morphological features
and immunocytochemical staining of neurogenic-related proteins
(NFM, NGF, and TRKA) revealed that SF-MSCs showed a strong
tendency to differentiate into neurocytes.
The differentiation capacity of SF-MSCs into chondrocytes is a
great signiﬁcance in the regeneration of cartilages in damaged
and inﬂamed articular joints in RA and OA. In a previous
comparative analysis of SF-MSCs and BM-MSCs, the chondrogenic
potential of the former with scaffolds was consistent, whereas
that of BM-MSCs was variable [11]. To the best of our knowledge,there has been no comparative analysis of chondrogenesis-related
gene expression with SF- and BM-MSCs in an isogenic back-
ground. In the present study, after 3 weeks of induction, the
chondrogenic potential of SF-MSCs was more stable than that of
BM-MSCs. In addition, the expression of chondrocyte-related
genes was higher in SF-MSCs compared to BM-MSCs. Moreover,
immunocytochemical staining for ACAN expression showed that
it was expressed in SF-MSCs in the center area of chondrogenic
pellets. The intensity of staining in SF-MSCs was signiﬁcantly
stronger than in BM-MSCs, and it increased with the passage of
time. Consequently, MSCs derived from SF, such as articular
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capacities, and they have greater chondrogenic potential than
BM-MSCs.
In vivo studies [4,5,7,8] have evaluated the therapeutic potential of
MSCs in treating RA. In humans, autologous adipose tissue-derived
MSCs (6108 or 8108 cells) were injected i.v. into RA patients
(n¼3) [35], and that the clinical status of the patients improved 3–13
months after the treatment. However, optimal methods for the
systemic injection of MSCs and the efﬁcacy of this treatment have
yet to be established in mouse and human models. The ﬁrst report by
Djouad et al. [4] administered an immortalized C3 mouse mesench-
ymal cell line i.v. into CIA mice and showed that these cells had no
beneﬁcial effects on RA symptoms or pathology, although the same
cells showed immunosuppressive potential in vitro. In contrast, a
single i.p. injection of allogeneic MSCs (5106 cells/mouse) in mice
prevented the development of severe arthritis [5]. Furthermore,
positive results were reported following multiple injections of
xenogenic MSCs (ﬁve i.p. injections of 5106 cells/mouse and
1106 cells/mouse ) [7,36] and allogeneic MSCs (three injections
i.v of 1106 cells/mouse and two injections i.v. of 1106 cells/
mouse) were also shown to yield promising results [6,37]. These
discrepancies of the systemic injection protocols for RA therapy may
originate from various factors, including the difference in types
(allogeneic or xenogenic) and tissue sources of MSCs, as well as the
dose of MSCs injected with different application methods (i.p. or i.v.).
However, MSC-dependent immunosuppression properties have not
yet been investigated in a CIA mouse. Nevertheless, as shown in the
above-mentioned studies [5,7,36], i.p. administration of at least
5106 MSCs/mouse may have exerted a therapeutic effect in a CIA
mouse model. In the present study, we modiﬁed the protocols
described by Liu et al. [7] and Gonzalez et al. [36], and the CIA mice
received an i.p. injection of 3106 BM-MSCs or SF-MSCs for 5 days,
and we then studied the therapeutic effect.
MSCs are not innately immunosuppressive but acquire this valuable
function in response to combination by chemokines, adhesion
molecules, and immunosuppressive molecules, and ultimately indo-
leamine 2,3-dioxygenase (IDO) or inducible nitric oxide synthase
(iNOS) [25]. The utilization of IDO and iNOS by MSCs in mediating
immunosuppression is species speciﬁc, with MSCs from humans and
pigs exploiting IDO and MSCs from mouse exploiting iNOS [15]. As
pigs have similar genetic and physiological characteristics to humans
[26], the porcine model may provide important insights into under-
standing of the regulation of immune response by MSCs and facilitate
the application of MSCs in human therapies. Furthermore, MSCs
have a property of immune tolerance and it’s not possessing immune
rejection, therefore it could be used in the allogeneic or xenogenic
stetting without the need for immunosuppression and cell/tissue
transplantation. Especially, in vivo immunosuppression studies has
been reported that there was positive effect of the systemic injection
of xenogenic MSC therapy for the repair of the systemic lupus
erythematosus (human BM-MSCs, [38]) and RA (human adipose-
MSCs, [36]; human umbilical cord blood-MSCs, [7]). In this study,
systemic administration of minipig SF-MSCs in established CIA mice
signiﬁcantly ameliorated both of the histopathologic and clinical
severity of the disease despite of this therapeutic effect was xeno-
geneic. According to those results, the immunosuppressive action of
SF-MSCs is unrestricted for major histocompatibility complex, and
infused SF-MSCs are sufﬁciently well immunotolerated by the host.
For in vivo evaluation of the potential of MSCs in the treatment
of RA, we administered 3106 BM- and SF-MSCs to a CIA mouseby systemic i.p. injection and then analyzed the effects of BM-
MSCs and SF-MSCs on the production of inﬂammatory mediators
linked to CIA in mice. TNF-α, IL-6 and IL-1β are important pro-
inﬂammatory cytokines known to play a signiﬁcant role in the
pathogenesis of RA [39]. Hence, we measured the levels of the
pro-inﬂammatory cytokines in the SF-MSCs injected CIA mice.
The levels of TNF-α and IL-6 in both the BM- and SF-MSCs injected
CIA mice were relatively lower than those in the control, but they
did not signiﬁcantly change among the groups. However, the
SF-MSCs signiﬁcantly decreased the level of IL-1β in the CIA mice
compared to the control and the BM-MSCs injected CIA mice.
Previous studies reported that the level of IL-1β increased in
inﬂamed synovial tissue and synovial ﬂuid of RA patients and that
the level of IL-1β was involved in local disease activity in RA [40–
42]. The therapeutic potential of the IL-1 receptor antagonist
(IL-1Ra) in RA has been studied and applied in clinical treatment
for RA patients [43]. IL-1Ra was shown to possess the ability to
reduce mononuclear cell inﬁltration in synovial membrane and
arrest progressive joint damage, which may be relevant to IL-1β-
mediated pathogenic effects [43].
The anti-inﬂammatory cytokine IL-10 has important roles in
relief from inﬂammation originating from autoimmune disease.
As shown in Fig. 7D, the increasing of IL-10 in the ankle and
serum of the SF-MSCs treated CIA mice in the present study
conﬁrmed the activation of anti-inﬂammatory and immunomo-
dulatory mechanisms in immune-related cells. In humans, despite
numerous studies of BM- and umbilical cord-derived MSCs, the
exact molecular mechanism through which MSCs exert their
immunosuppressive effects are still not known [7]. Research has
demonstrated that IL-10 is a relevant soluble factor in MSCs [44–
46]. Together with earlier reports [47–49], our ﬁndings suggest
that the observed anti-arthritic effects are to the SF-MSCs treat-
ment increasing the levels of IL-10.
The histological assessments of the arthritis-induced joints in
the CIA mice pointed to inﬂammation or bone and cartilage
damage in the inﬂamed joints of RA. As shown in Fig. 7A and B,
synovial inﬂammation and bone and cartilage damage were
signiﬁcantly (Po0.01) lower in the SF-MSCs injected CIA mice
than in the control and/or BM-MSCs injected CIA mice. RA is
characterized by articular cartilage destruction and massive bone
resorption, which results in the expression of RANKL in inﬂamed
RA joints, and the inhibition of RANKL was reported to completely
prevent bone loss and to partially protect cartilage [50]. Therefore,
the low level of osteoclast-related sRANKL (Fig. 7D) in the RA
joints of both the SF-MSCs and BM-MSCs injected CIA mice might
explain the low level of bone erosion (Fig. 7A and B), with the
level of bone erosion decreased signiﬁcantly in the SF-MSCs
injected mice compared with the control and the BM-MSCs
injected mice (Po0.01 or Po0.05, respectively). The major
sources of RANKL are activated T cells [51,52], and these
RANKL-positive T cells may come into contact with osteoclast
precursors [53]. Furthermore, these RANKL-positive T cells have a
high capacity to produce pro-inﬂammatory cytokines, which
stimulate the expression of RANKL by ﬁbroblast-like synoviocytes
[54]. Therefore, the low level of sRANKL observed in the present
study may have arrested bone erosion and cartilage damage, also
the release of pro-inﬂammatory cytokines in the SF-MSCs injected
CIA mice compared to the BM-MSCs injected CIA mice.
Moreover, Jiang et al. [50] found that the expression of the
RANKL transcript was much higher in aged or female cells than in
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much higher than normal in RA and OA. RA patients are mainly
aged females, and bone-resorbing osteoclasts in the synovium
play an important role in bone destruction in RA [49]. Therefore,
reducing the level of sRANKL expression by injection of both types
of MSCs, especially SF-MSCs, may have potential in autologous RA
therapy.
We determined that BM-MSCs were capable of reducing the
clinical scores of arthritic legs but that they did not exert a
therapeutic effect on other evaluated factors, such as inﬂamma-
tion associated with cytokine release and histological damage,
except the low level of bone erosion and sRANKL. According to
previous reports [6,37,55,56], it is difﬁcult to clarify the immu-
nomodulatory role of BM-MSCs in CIA mice, despite the tradi-
tional role of BM-MSCs in various stem cell therapies. Schurgers
et al. [55] and Chen et al. [56] were unable to demonstrate any
beneﬁt of allogenic BM-MSC therapy for CIA mice, despite other
studies reporting positive clinical effects [5,6]. In contrast to the
injection of IL-10-transduced BM-MSCs, the systemic injection of
naive BM-MSCs did not affect the severity of arthritis in CIA mice
[37]. Therefore, IL-10 transduced-BM-MSCs rather than naive BM-
MSCs may be useful for treating RA. Moreover, Boufﬁ et al. [6]
suggested that the systemic injection of BM-MSCs might prevent
RA, but they found that it did not have a therapeutic effect on CIA
mice. The ﬁndings of the aforementioned studies are similar to
those of our study. We found that BM-MSCs were capable of
reducing the clinical scores of arthritic legs but that they did not
exert a therapeutic effect on other evaluated factors, such as
inﬂammation associated with cytokine release and histological
damage, except the low level of bone erosion and sRANKL.
However, SF-MSCs showed a greater ability to improve these
factors compared to BM-MSCs, and they can be successfully
employed in RA therapy.
To date, immunotherapy for RA aimed at inhibiting levels of
pro-inﬂammatory cytokines has targeted RA symptoms [57], but
that may play a pivotal role in regulating anti-inﬂammatory
cytokines, including IL-10, which has a protective role as an
endogenous inhibitor in inﬂammation in RA [58,59]. In addition,
as shown in the above-mentioned study by Choi et al. [37], IL-10-
transduced MSCs have therapeutic potential in reducing arthritis
by regulating other cytokines, such as IL-6 or IL-4. We observed an
increased level of IL-10 in the ankles and serum of the SF-MSCs
injected CIA mice, suggesting that there is no need for genetic
manipulation to obtain a higher level of IL-10. Moreover, SF-MSCs
were capable of reducing the level of pro-inﬂammatory cytokine
IL-1β in the ankles of the CIA mice, which inhibition of IL-1β is
used to treat RA patients in the clinic.
The present study revealed that the proliferation capacity,
expression of transcription factors, and immunosuppressive prop-
erties of MSCs varied according to the source from which the cells
were derived. The proliferation capacity and chondrogenic differ-
entiation ability of MSCs derived from SF were superior to those
derived from BM. With regard to immunosuppression, BM- and
SF-MSCs have great clinical potential for reducing the symptoms
of RA and the expression of sRANKL. In the present study,
injection of SF-MSCs into CIA mice increased the level of the
anti-inﬂammatory cytokine IL-10 and decreased the level of the
pro-inﬂammatory cytokine IL-1β, it also reduced inﬂammatory
responses in ankles, indicating that SF-MSCs have potential in the
treatment of RA.Based on these results, we hypothesize that immunosuppres-
sion by MSCs derived from different sources within the same
donor may affect proliferation capacity and Oct3/4 expression
during in vitro culture. Additional injections of SF-MSCs in an RA
mouse model may lead to cartilage regeneration and complete
recovery by immunosuppressive modulation.Disclosure statement
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